PNA FISH™ receives Frost & Sullivan’s Rapid In Vitro
Diagnostic Technology Innovation of the Year Award

PNA FISH™ received Frost & Sullivan’s 2008 Technology Innovation of the Year Award in the field of rapid in vitro molecular diagnostic technology. The award recognizes how hospitals depend on AdvanDx’s easy-to-use, molecular-based PNA FISH diagnostics to quickly identify bloodstream pathogens in hours instead of days. The rapid PNA FISH results enable laboratories to report critical information to physicians and pharmacists earlier to help optimize therapy and reduce mortality rates for patients afflicted with bloodstream infections.¹

Research Methodology and Selection Process Criteria
To choose The Technology Innovation of the Year Award recipient, Frost & Sullivan’s analyst team conducted a selection process that included primary interviews and extensive primary and secondary research via a bottom-up approach. The analyst team considered AdvanDx’s pace of research and technology innovation and its significance and relevance to the overall industry. The ultimate Award recipient was selected after a thorough evaluation of this research.

The recipient of the Award has excelled based on the following criteria:

• Significance of technology in the industry
• Potential of technology/products to become an industry standard
• Competitive advantage of technology when compared to competing technologies
• Ease of adoption of technology
• Breadth of intellectual property related to the innovation (e.g., patents, coverage in scientific publications, papers and in peer reviewed articles).

For more information, visit www.frost.com.

¹ Ly T, Gulia J, Pyrgos V, Waga M, Shoham S. 2008. Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Therapeutics and Clinical Risk Management, in press, dovepress.com/articles.php?journal_id=68

Return to bioMérieux Connection, April 2008